China Universal Asset Management Company’s Allogene Therapeutics ALLO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$114K Buy
54,931
+15,051
+38% +$33.1K 0.01% 404
2026
Q1
$97.3K Buy
39,880
+3,260
+9% +$6.53K 0.01% 405
2025
Q4
$50.2K Sell
36,620
-2,272
-6% -$3K ﹤0.01% 451
2025
Q3
$48.2K Sell
38,892
-5,039
-11% -$6.01K ﹤0.01% 436
2025
Q2
$49.6K Buy
43,931
+1,874
+4% +$2.49K ﹤0.01% 420
2025
Q1
$61.4K Sell
42,057
-2,401
-5% -$4.53K 0.01% 399
2024
Q4
$94.7K Buy
44,458
+4,239
+11% +$10.5K 0.01% 398
2024
Q3
$113K Buy
40,219
+15,690
+64% +$41.8K 0.01% 349
2024
Q2
$57.2K Sell
24,529
-7,819
-24% -$23.1K 0.01% 347
2024
Q1
$145K Buy
32,348
+12,881
+66% +$53.7K 0.02% 330
2023
Q4
$62.5K Buy
19,467
+15,170
+353% +$43K 0.01% 344
2023
Q3
$13.6K Buy
4,297
+2,385
+125% +$10.5K ﹤0.01% 327
2023
Q2
$9.5K Sell
1,912
-46
-2% -$249 ﹤0.01% 323
2023
Q1
$9.67K Buy
1,958
+493
+34% +$3.16K ﹤0.01% 296
2022
Q4
$9.21K Buy
1,465
+118
+9% +$1.09K ﹤0.01% 235
2022
Q3
$15K Buy
+1,347
New +$18.3K 0.01% 170

Other funds holding ALLO

China Universal Asset Management Company's ALLO Position: Q2 2026 in Review

China Universal Asset Management Company increased its Allogene Therapeutics (ALLO) stake by 38% in Q2 2026, buying an estimated $33.1K and bringing the position to 54,931 shares worth $114K. The position accounts for 0.01% of the portfolio, ranked #404.

China Universal Asset Management Company first reported a position in ALLO in Q3 2022 and has held it in 16 quarters since. The position peaked at $145K in Q1 2024. 27 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • China Universal Asset Management Company held 54,931 shares of Allogene Therapeutics worth $114K as of Q2 2026.
  • China Universal Asset Management Company bought 15,051 Allogene Therapeutics shares in Q2 2026, an estimated $33.1K.
  • Allogene Therapeutics made up 0.01% of China Universal Asset Management Company's portfolio in Q2 2026, its #404 holding.
  • China Universal Asset Management Company first reported a position in Allogene Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • China Universal Asset Management Company's Allogene Therapeutics position peaked at $145K in Q1 2024.
  • 27 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.